These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 929475)

  • 21. [Value of low-dose dopa therapy in Parkinson disease].
    Petit H; Rousseaux M; Mazingue A; Warot P
    LARC Med; 1983; 3(7):514-6. PubMed ID: 6645742
    [No Abstract]   [Full Text] [Related]  

  • 22. [L-dopa-decarboxylase inhibitor combination preparation (Sinemet) in parkinsonism and syndromes imitating parkinsonism. 1 year's experience with 34 patients].
    Holmsen R
    Tidsskr Nor Laegeforen; 1976 Feb; 96(4):225, 234-6. PubMed ID: 1251394
    [No Abstract]   [Full Text] [Related]  

  • 23. Enteric-coated L-dopa (prodopa). A new approach to L-dopa therapy in Parkinson's disease.
    Gilligan B; Hancock R
    Med J Aust; 1975 Nov; 2(22):824-6. PubMed ID: 1207582
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Improved therapeutic response to L-dopa in Parkinson's disease, when combined with bromocriptine (author's transl)].
    Ulm G
    Nervenarzt; 1981 Feb; 52(2):116-20. PubMed ID: 7219619
    [No Abstract]   [Full Text] [Related]  

  • 25. Augmenting procedures during L-dopa therapy for Parkinsonism.
    Bhaskar PA; Bhaskar EA; Jagannathan K
    J Assoc Physicians India; 1975 Jan; 23(1):21-7. PubMed ID: 1194194
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of L-dopa on EEG tracings in patients with parkinsonism].
    Rudkowska A; Misztal S
    Pol Tyg Lek; 1975 Apr; 30(14):593-5. PubMed ID: 1129202
    [No Abstract]   [Full Text] [Related]  

  • 27. [Unusual symptoms in Parkinsonism: positive effects of L-dopa].
    Morel-Maroger A; Therme F
    Therapie; 1978; 33(1):129-30. PubMed ID: 663891
    [No Abstract]   [Full Text] [Related]  

  • 28. [Juvenile parkinsonism. 18 cases].
    Ferreiro JL; Pugliese MI; Caride AE
    Medicina (B Aires); 1991; 51(3):204-8. PubMed ID: 1821902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. L-dopa, parkinsonism, and involuntary movements.
    Mayer RF
    Trans Am Neurol Assoc; 1974; 99():163-6. PubMed ID: 4463527
    [No Abstract]   [Full Text] [Related]  

  • 30. [Use of dihydroergotamine in the prevention and treatment of orthostatic hypotension syndromes in patients with parkinsonism treated with L-dopa].
    Jubert Gruart J; Balcells Riba M
    Arch Neurobiol (Madr); 1974; 37(4):401-12. PubMed ID: 4433212
    [No Abstract]   [Full Text] [Related]  

  • 31. [Effects and side effects to levodopa in parkinsonism- results of a collaborative study. (5) Combined therapy with a peripheral decarboxylase inhibitor].
    Omoto T
    Rinsho Shinkeigaku; 1976 Dec; 16(12):879-80. PubMed ID: 1035531
    [No Abstract]   [Full Text] [Related]  

  • 32. Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose.
    Granerus AK; Jagenburg R; Rödjer S; Svanborg A
    Acta Med Scand; 1974 Dec; 196(6):459-63. PubMed ID: 4456974
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of parkinsonism by L-dopa and dopa-decarboxylase inhibitor in a single tablet].
    Sarova-Pinhas I; Braham J
    Harefuah; 1974 Sep; 87(5):208-10. PubMed ID: 4435614
    [No Abstract]   [Full Text] [Related]  

  • 34. L-dopa-resistant Parkinsonism due to dopa decarboxylase deficiency?
    Jankovic J
    Ann Neurol; 1981 Jul; 10(1):64-5. PubMed ID: 7271235
    [No Abstract]   [Full Text] [Related]  

  • 35. [Early or late onset of L-dopa treatment in Parkinson disease?].
    von Kummer R; Schneevoigt K
    Nervenarzt; 1986 Nov; 57(11):634-9. PubMed ID: 3808131
    [No Abstract]   [Full Text] [Related]  

  • 36. Levodopa response in Parkinsonism with multiple mitochondrial DNA deletions.
    Wilcox RA; Churchyard A; Dahl HH; Hutchison WM; Kirby DM; Thyagarajan D
    Mov Disord; 2007 May; 22(7):1020-3. PubMed ID: 17357142
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Levodopa-free periods ("drug holidays") in the management of parkinsonism.
    Klawans HL; Goetz CG; Tanner CM; Nausieda PA; Weiner WJ
    Adv Neurol; 1983; 37():33-43. PubMed ID: 6858778
    [No Abstract]   [Full Text] [Related]  

  • 38. [The L-dopa test in Parkinson's disease].
    Esteguy M; Bonnet AM; Kefalos J; Lhermitte F; Agid Y
    Rev Neurol (Paris); 1985; 141(5):413-5. PubMed ID: 4048732
    [TBL] [Abstract][Full Text] [Related]  

  • 39. L-dopa plus dopa-decarboxylase inhibitor. Sleep organization in Parkinson's syndrome before and after treatment.
    Bergonzi P; Chiurulla C; Gambi D; Mennuni G; Pinto F
    Acta Neurol Belg; 1975; 75(1):5-10. PubMed ID: 1202895
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [An analysis of long-term L-dopa treatment on 122 cases of Parkinson's disease over 14 years--when should L-dopa therapy be initiated?].
    Indo T; Takahashi A
    Rinsho Shinkeigaku; 1986 Apr; 26(4):363-71. PubMed ID: 3731637
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.